Search

Your search keyword '"Jeeyun, Lee"' showing total 1,036 results

Search Constraints

Start Over You searched for: Author "Jeeyun, Lee" Remove constraint Author: "Jeeyun, Lee"
1,036 results on '"Jeeyun, Lee"'

Search Results

1. TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice

Catalog

Books, media, physical & digital resources

3. Clinically conserved genomic subtypes of gastric adenocarcinoma

4. Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer

5. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

6. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors

8. 613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

9. 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

10. 729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors

11. ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer

12. Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

13. Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data

14. Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer

15. One-step achievement of tumor spheroid-induced angiogenesis in a high-throughput microfluidic platform: one-step tumor angiogenesis platform

16. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

18. MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

19. Reducing tumor invasiveness by ramucirumab and TGF‐β receptor kinase inhibitor in a diffuse‐type gastric cancer patient‐derived cell model

20. Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study

21. Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer

22. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

23. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

24. Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

25. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars

26. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

27. Comprehensive pharmacogenomic characterization of gastric cancer

28. The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers

29. 409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

30. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer

31. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

32. Clinical outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision in locally advanced rectal cancer with mesorectal fascia involvement.

33. Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer

34. Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study

35. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma

36. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

37. Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

38. Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue

39. Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

40. Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial

41. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

42. Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody

43. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

44. Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer

45. Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

47. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

48. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

49. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea.

50. First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients